Opatanol (olopatadine)
- Region
- 🇪🇺 EU
- Active substance
- olopatadine
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Conjunctivitis, Allergic
- EU approval
- Thu 16 May 2002
- Application
- EMEA/H/C/000407
- ATC
- S01GX09
- Official record
- www.ema.europa.eu
Indication
Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
Regulatory milestones
No milestones recorded in the last year.
Follow Opatanol
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.